www.fdanews.com/articles/198311-janssens-stelara-approved-for-plaque-psoriasis-in-children
Janssen’s Stelara Approved for Plaque Psoriasis in Children
August 3, 2020
The FDA has approved Janssen’s Stelara (ustekinumab) for the treatment of children ages 6-11 years old with skin lesions associated with moderate to severe plaque psoriasis.
The approval was based on the results of a phase 3 trial of 44 patients in which 77 percent of participants achieved clear or almost clear skin at week 12 after two doses.
Stelara targets interleukin (IL)-12 and IL-23, two inflammatory cytokines produced by the immune system.